Published in Biochem J on July 01, 2006
Sex differences in the expression of hepatic drug metabolizing enzymes. Mol Pharmacol (2009) 2.45
Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-{beta} and STAT3 activation. J Exp Med (2009) 1.39
Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver. Mol Cell Biol (2011) 1.36
Regulation of hepatic bile acid transporters Ntcp and Bsep expression. Biochem Pharmacol (2007) 1.10
Sexual dimorphism in hepatic gene expression and the response to dietary carbohydrate manipulation in the zebrafish (Danio rerio). Comp Biochem Physiol Part D Genomics Proteomics (2008) 0.98
Alterations in hepatic mRNA expression of phase II enzymes and xenobiotic transporters after targeted disruption of hepatocyte nuclear factor 4 alpha. Toxicol Sci (2010) 0.88
TREMOR--a tool for retrieving transcriptional modules by incorporating motif covariance. Nucleic Acids Res (2007) 0.82
Role of PPARα and HNF4α in stress-mediated alterations in lipid homeostasis. PLoS One (2013) 0.82
Increased SULT1E1 activity in HepG2 hepatocytes decreases growth hormone stimulation of STAT5b phosphorylation. Steroids (2008) 0.82
Crosstalk of HNF4α with extracellular and intracellular signaling pathways in the regulation of hepatic metabolism of drugs and lipids. Acta Pharm Sin B (2016) 0.81
Disruption of STAT5b-Regulated Sexual Dimorphism of the Liver Transcriptome by Diverse Factors Is a Common Event. PLoS One (2016) 0.77
Cross Talk Between GH-Regulated Transcription Factors HNF6 and CUX2 in Adult Mouse Liver. Mol Endocrinol (2015) 0.77
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02
Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis. Mol Cell Biol (2001) 8.95
Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell (1998) 5.92
Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc Natl Acad Sci U S A (1997) 4.11
Liver-enriched transcription factors and hepatocyte differentiation. FASEB J (1996) 3.18
TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. J Biol Chem (2001) 2.65
Activation of Jak2 catalytic activity requires phosphorylation of Y1007 in the kinase activation loop. Mol Cell Biol (1997) 2.51
Rapid actions of plasma membrane estrogen receptors. Trends Endocrinol Metab (2001) 2.42
Growth hormone regulation of sex-dependent liver gene expression. Mol Endocrinol (2006) 2.37
The maturity-onset diabetes of the young (MODY1) transcription factor HNF4alpha regulates expression of genes required for glucose transport and metabolism. Proc Natl Acad Sci U S A (1997) 2.18
Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol (2006) 2.17
Inhibitors of cytokine signal transduction. J Biol Chem (2003) 2.10
Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure (2002) 2.10
Crystal structure of the HNF4 alpha ligand binding domain in complex with endogenous fatty acid ligand. J Biol Chem (2002) 1.99
HNF4: a central regulator of hepatocyte differentiation and function. Hepatology (2003) 1.84
The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med (2003) 1.81
Temporal relationship between the sexually dimorphic spontaneous GH secretory profiles and hepatic STAT5 activity. Endocrinology (2001) 1.74
Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab (2001) 1.73
DNA binding site selection of dimeric and tetrameric Stat5 proteins reveals a large repertoire of divergent tetrameric Stat5a binding sites. Mol Cell Biol (2000) 1.68
Transcriptional regulation of the human sterol 12alpha-hydroxylase gene (CYP8B1): roles of heaptocyte nuclear factor 4alpha in mediating bile acid repression. J Biol Chem (2001) 1.54
Interferon-gamma induces tyrosine phosphorylation of interferon-gamma receptor and regulated association of protein tyrosine kinases, Jak1 and Jak2, with its receptor. J Biol Chem (1994) 1.46
Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice. Mol Endocrinol (2004) 1.46
Retracted A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b. J Biol Chem (2000) 1.45
The coactivator PGC-1 is involved in the regulation of the liver carnitine palmitoyltransferase I gene expression by cAMP in combination with HNF4 alpha and cAMP-response element-binding protein (CREB). J Biol Chem (2002) 1.41
Retracted A nuclear protein tyrosine phosphatase TC-PTP is a potential negative regulator of the PRL-mediated signaling pathway: dephosphorylation and deactivation of signal transducer and activator of transcription 5a and 5b by TC-PTP in nucleus. Mol Endocrinol (2002) 1.33
Codependence of growth hormone-responsive, sexually dimorphic hepatic gene expression on signal transducer and activator of transcription 5b and hepatic nuclear factor 4alpha. Mol Endocrinol (2005) 1.29
Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. Growth Factors (2004) 1.29
Cytochrome P450 regulation by hepatocyte nuclear factor 4 in human hepatocytes: a study using adenovirus-mediated antisense targeting. Hepatology (2001) 1.27
Short-chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood (2001) 1.19
Estrogen inhibits GH signaling by suppressing GH-induced JAK2 phosphorylation, an effect mediated by SOCS-2. Proc Natl Acad Sci U S A (2003) 1.18
Negative regulation of T cell antigen receptor signal transduction by hematopoietic tyrosine phosphatase (HePTP). J Biol Chem (1998) 1.18
Genotype/phenotype relationships in HNF-4alpha/MODY1: haploinsufficiency is associated with reduced apolipoprotein (AII), apolipoprotein (CIII), lipoprotein(a), and triglyceride levels. Diabetes (2000) 1.15
Mutation of the SHP-2 binding site in growth hormone (GH) receptor prolongs GH-promoted tyrosyl phosphorylation of GH receptor, JAK2, and STAT5B. Mol Endocrinol (2000) 1.13
Plasma growth hormone pulse activation of hepatic JAK-STAT5 signaling: developmental regulation and role in male-specific liver gene expression. Endocrinology (2000) 1.10
Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation. Mol Endocrinol (1997) 1.10
Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Toxicol Appl Pharmacol (2004) 1.08
Interactions in the transcriptional regulation exerted by Stat5 and by members of the steroid hormone receptor family. J Steroid Biochem Mol Biol (1999) 1.06
Cross-talk between ERs and signal transducer and activator of transcription 5 is E2 dependent and involves two functionally separate mechanisms. Mol Endocrinol (2001) 1.04
Identification of protein tyrosine phosphatases with specificity for the ligand-activated growth hormone receptor. Mol Endocrinol (2003) 0.97
Polyunsaturated fatty acyl coenzyme A suppress the glucose-6-phosphatase promoter activity by modulating the DNA binding of hepatocyte nuclear factor 4 alpha. J Biol Chem (2002) 0.96
Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression. J Biol Chem (1997) 0.95
Termination of growth hormone pulse-induced STAT5b signaling. Mol Endocrinol (1999) 0.95
Developmental action of estrogen receptor-alpha feminizes the growth hormone-Stat5b pathway and expression of Cyp2a4 and Cyp2d9 genes in mouse liver. Mol Pharmacol (1999) 0.94
Serine phosphorylation of GH-activated signal transducer and activator of transcription 5a (STAT5a) and STAT5b: impact on STAT5 transcriptional activity. Mol Endocrinol (2001) 0.93
Role of hepatocyte nuclear factors in transcriptional regulation of male-specific CYP2A2. J Biol Chem (2004) 0.93
Inhibitory cross-talk between STAT5b and liver nuclear factor HNF3beta: impact on the regulation of growth hormone pulse-stimulated, male-specific liver cytochrome P-450 gene expression. J Biol Chem (2001) 0.91
STAT5b down-regulates peroxisome proliferator-activated receptor alpha transcription by inhibition of ligand-independent activation function region-1 trans-activation domain. J Biol Chem (1999) 0.90
Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. Mol Pharmacol (2003) 0.89
Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. Biochemistry (1995) 0.87
Regulation of the trans-activation potential of STAT5 through its DNA-binding activity and interactions with heterologous transcription factors. Growth Horm IGF Res (2000) 0.85
Differential protein binding and transcriptional activities of HNF-4 elements in three closely related CYP2C genes. DNA Cell Biol (1994) 0.85
Two initiator-like elements are required for the combined activation of the human apolipoprotein C-III promoter by upstream stimulatory factor and hepatic nuclear factor-4. J Biol Chem (2002) 0.82
Transcriptional regulation by HNF-4 of the steroid 15alpha-hydroxylase P450 (Cyp2a-4) gene in mouse liver. J Steroid Biochem Mol Biol (1997) 0.81
Cooperative regulation of CYP2C12 gene expression by STAT5 and liver-specific factors in female rats. J Biol Chem (1999) 0.80
Fatty acids inhibit leptin signalling in BRIN-BD11 insulinoma cells. J Mol Endocrinol (2001) 0.79
Cross-talk between signal transducer and activator of transcription (Stat5) and thyroid hormone receptor-beta 1 (TRbeta1) signaling pathways. Mol Endocrinol (2000) 0.78
Activation of PPARalpha and PPARgamma by environmental phthalate monoesters. Toxicol Sci (2003) 2.20
Sex-dependent liver gene expression is extensive and largely dependent upon signal transducer and activator of transcription 5b (STAT5b): STAT5b-dependent activation of male genes and repression of female genes revealed by microarray analysis. Mol Endocrinol (2006) 2.17
Combination of antiangiogenesis with chemotherapy for more effective cancer treatment. Mol Cancer Ther (2008) 1.96
MAnorm: a robust model for quantitative comparison of ChIP-Seq data sets. Genome Biol (2012) 1.88
Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient mice. Mol Endocrinol (2004) 1.46
Unbiased, genome-wide in vivo mapping of transcriptional regulatory elements reveals sex differences in chromatin structure associated with sex-specific liver gene expression. Mol Cell Biol (2010) 1.45
Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology (2007) 1.39
Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver. Mol Cell Biol (2011) 1.36
Liver-specific hepatocyte nuclear factor-4alpha deficiency: greater impact on gene expression in male than in female mouse liver. Mol Endocrinol (2008) 1.30
Sexual dimorphism of rat liver gene expression: regulatory role of growth hormone revealed by deoxyribonucleic Acid microarray analysis. Mol Endocrinol (2003) 1.30
Codependence of growth hormone-responsive, sexually dimorphic hepatic gene expression on signal transducer and activator of transcription 5b and hepatic nuclear factor 4alpha. Mol Endocrinol (2005) 1.29
Role of hepatocyte nuclear factors in growth hormone-regulated, sexually dimorphic expression of liver cytochromes P450. Growth Factors (2004) 1.29
Role of STAT5a in regulation of sex-specific gene expression in female but not male mouse liver revealed by microarray analysis. Physiol Genomics (2007) 1.20
Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol Cancer Ther (2008) 1.19
Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5. Mol Endocrinol (2009) 1.12
The structural basis of pregnane X receptor binding promiscuity. Biochemistry (2009) 1.09
Dynamic in vivo binding of STAT5 to growth hormone-regulated genes in intact rat liver. Sex-specific binding at low- but not high-affinity STAT5 sites. Mol Endocrinol (2009) 1.09
Sex-specific early growth hormone response genes in rat liver. Mol Endocrinol (2008) 1.08
Simultaneous, bidirectional inhibitory crosstalk between PPAR and STAT5b. Toxicol Appl Pharmacol (2004) 1.08
Directed evolution of mammalian cytochrome P450 2B1: mutations outside of the active site enhance the metabolism of several substrates, including the anticancer prodrugs cyclophosphamide and ifosfamide. J Biol Chem (2005) 1.06
Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab Rev (2006) 1.06
Growth hormone determines sexual dimorphism of hepatic cytochrome P450 3A4 expression in transgenic mice. J Pharmacol Exp Ther (2005) 1.06
Transcriptional profiling of human liver identifies sex-biased genes associated with polygenic dyslipidemia and coronary artery disease. PLoS One (2011) 1.06
Intrinsic sex differences in the early growth hormone responsiveness of sex-specific genes in mouse liver. Mol Endocrinol (2010) 1.05
Enhanced antitumor activity of P450 prodrug-based gene therapy using the low Km cyclophosphamide 4-hydroxylase P450 2B11. Mol Cancer Ther (2006) 1.05
VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res (2012) 1.05
Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Mol Pharmacol (2004) 1.04
Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver. Mol Cell Biol (2013) 1.03
Characterization of three growth hormone-responsive transcription factors preferentially expressed in adult female liver. Endocrinology (2007) 1.03
Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. Biochemistry (2005) 1.02
Dominant effect of antiangiogenesis in combination therapy involving cyclophosphamide and axitinib. Clin Cancer Res (2009) 1.01
Role of the cytokine-induced SH2 domain-containing protein CIS in growth hormone receptor internalization. J Biol Chem (2005) 1.01
trans-activation of PPARalpha and induction of PPARalpha target genes by perfluorooctane-based chemicals. Toxicol Sci (2004) 1.00
A mouse model with liver-specific deletion and global suppression of the NADPH-cytochrome P450 reductase gene: characterization and utility for in vivo studies of cyclophosphamide disposition. J Pharmacol Exp Ther (2007) 0.99
Sex-specific mouse liver gene expression: genome-wide analysis of developmental changes from pre-pubertal period to young adulthood. Biol Sex Differ (2012) 0.98
Conditionally replicating adenoviruses for cancer treatment. Curr Cancer Drug Targets (2007) 0.98
PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesis. Mol Cancer (2010) 0.97
Collaboration between hepatic and intratumoral prodrug activation in a P450 prodrug-activation gene therapy model for cancer treatment. Mol Cancer Ther (2007) 0.97
Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapy. Cancer Res (2004) 0.96
Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methylcholanthrene. Toxicol Appl Pharmacol (2005) 0.96
Mouse lung CYP1A1 catalyzes the metabolic activation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). Carcinogenesis (2006) 0.95
Antiangiogenesis enhances intratumoral drug retention. Cancer Res (2011) 0.95
Role of hepatocyte nuclear factors in transcriptional regulation of male-specific CYP2A2. J Biol Chem (2004) 0.93
Interactions of methoxyacetic acid with androgen receptor. Toxicol Appl Pharmacol (2008) 0.93
Environmental phthalate monoesters activate pregnane X receptor-mediated transcription. Toxicol Appl Pharmacol (2004) 0.92
Impact of CUX2 on the female mouse liver transcriptome: activation of female-biased genes and repression of male-biased genes. Mol Cell Biol (2012) 0.91
Activation of oxazaphosphorines by cytochrome P450: application to gene-directed enzyme prodrug therapy for cancer. Toxicol In Vitro (2005) 0.90
Enantioselective metabolism and cytotoxicity of R-ifosfamide and S-ifosfamide by tumor cell-expressed cytochromes P450. Drug Metab Dispos (2005) 0.90
Down-regulation of STAT5b transcriptional activity by ligand-activated peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma. Mol Pharmacol (2003) 0.89
Sexual dimorphism of rat liver nuclear proteins: regulatory role of growth hormone. Mol Cell Proteomics (2004) 0.88
Sustained P450 expression and prodrug activation in bolus cyclophosphamide-treated cultured tumor cells. Impact of prodrug schedule on P450 gene-directed enzyme prodrug therapy. Cancer Gene Ther (2003) 0.87
Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletions. Hum Gene Ther (2008) 0.87
Re-engineering cytochrome P450 2B11dH for enhanced metabolism of several substrates including the anti-cancer prodrugs cyclophosphamide and ifosfamide. Arch Biochem Biophys (2007) 0.87
Cancer chemotherapy and drug metabolism. Drug Metab Dispos (2005) 0.87
Spectrophotometric analysis of human CYP2E1-catalyzed p-nitrophenol hydroxylation. Methods Mol Biol (2006) 0.86
Computational screening of phthalate monoesters for binding to PPARgamma. Chem Res Toxicol (2006) 0.85
Impact of dimethyl sulfoxide on expression of nuclear receptors and drug-inducible cytochromes P450 in primary rat hepatocytes. Arch Biochem Biophys (2004) 0.85
Computational solvent mapping reveals the importance of local conformational changes for broad substrate specificity in mammalian cytochromes P450. Biochemistry (2006) 0.85
Cytochrome P450 gene-directed enzyme prodrug therapy (GDEPT) for cancer. Curr Pharm Des (2002) 0.84
Toxicity of ethylene glycol monomethyl ether: impact on testicular gene expression. Int J Androl (2007) 0.84
Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett (2012) 0.83
Regulation of human CYP2C18 and CYP2C19 in transgenic mice: influence of castration, testosterone, and growth hormone. Drug Metab Dispos (2009) 0.83
Targeting drug-metabolizing enzymes for effective chemoprevention and chemotherapy. Drug Metab Dispos (2010) 0.82
Wavelength-dependent backscattering measurements for quantitative monitoring of apoptosis, part 1: early and late spectral changes are indicative of the presence of apoptosis in cell cultures. J Biomed Opt (2011) 0.82
Impact of methoxyacetic acid on mouse Leydig cell gene expression. Reprod Biol Endocrinol (2010) 0.82
Complex modulation of androgen responsive gene expression by methoxyacetic acid. Reprod Biol Endocrinol (2011) 0.82
The induction of atherogenic dyslipidaemia in poloxamer 407-treated mice is not mediated through PPARalpha. J Pharm Pharmacol (2008) 0.82
DNase I digestion of isolated nulcei for genome-wide mapping of DNase hypersensitivity sites in chromatin. Methods Mol Biol (2013) 0.81
Enhanced bystander cytotoxicity of P450 gene-directed enzyme prodrug therapy by expression of the antiapoptotic factor p35. Cancer Res (2002) 0.81
Pregnane X receptor-mediated transcription. Methods Enzymol (2005) 0.81
Antitumor activity of methoxymorpholinyl doxorubicin: potentiation by cytochrome P450 3A metabolism. Mol Pharmacol (2004) 0.81
Wavelength-dependent backscattering measurements for quantitative monitoring of apoptosis, part 2: early spectral changes during apoptosis are linked to apoptotic volume decrease. J Biomed Opt (2011) 0.81
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model. Mol Cancer Ther (2013) 0.80
Elevated basal expression of liver peroxisomal beta-oxidation enzymes and CYP4A microsomal fatty acid omega-hydroxylase in STAT5b(-/-) mice: cross-talk in vivo between peroxisome proliferator-activated receptor and signal transducer and activator of transcription signaling pathways. Toxicol Appl Pharmacol (2002) 0.80
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantrone. J Pharmacol Exp Ther (2012) 0.79
Changes in mouse uterine transcriptome in estrus and proestrus. Biol Reprod (2013) 0.79
Identification of novel enzyme-prodrug combinations for use in cytochrome P450-based gene therapy for cancer. Arch Biochem Biophys (2003) 0.79
Cytochrome-P450 2B1 gene silencing attenuates puromycin aminonucleoside-induced cytotoxicity in glomerular epithelial cells. Kidney Int (2010) 0.79
Evaluation of thyroid hormone effects on liver P450 reductase translation. Arch Biochem Biophys (2003) 0.77
Adenoviral delivery of pan-caspase inhibitor p35 enhances bystander killing by P450 gene-directed enzyme prodrug therapy using cyclophosphamide+. BMC Cancer (2010) 0.77
Isolation of nuclei for use in genome-wide DNase hypersensitivity assays to probe chromatin structure. Methods Mol Biol (2013) 0.77
Determination of CYP2B6 component of 7-ethoxy-4-trifluoromethylcoumarin O-deethylation activity in human liver microsomes. Methods Mol Biol (2006) 0.77
Post-transcriptional regulation of hepatic NADPH-cytochrome P450 reductase by thyroid hormone: independent effects on poly(A) tail length and mRNA stability. Mol Pharmacol (2002) 0.76
CYP2D6-dependent bufuralol 1'-hydroxylation assayed by reverse-phase ion-pair high-performance liquid chromatography with fluorescence detection. Methods Mol Biol (2006) 0.76
Determination of CYP4A11-catalyzed lauric acid 12-hydroxylation by high-performance liquid chromatography with radiometric detection. Methods Mol Biol (2006) 0.76
Enzymatic analysis of cDNA-expressed human CYP1A1, CYP1A2, and CYP1B1 with 7-ethoxyresorufin as substrate. Methods Mol Biol (2006) 0.76
Determination of CYP2C9-catalyzed diclofenac 4'-hydroxylation by high-performance liquid chromatography. Methods Mol Biol (2006) 0.76
Circulating free fatty acids are increased independently of PPARgamma activity after administration of poloxamer 407 to mice. Can J Physiol Pharmacol (2008) 0.75
Correction: Chemical and Hormonal Effects on STAT5b- Dependent Sexual Dimorphism of the Liver Transcriptome. PLoS One (2016) 0.75
Cytochrome p450-based gene therapies for cancer. Methods Mol Med (2004) 0.75
Cytochrome P450 2B1 mediates complement-dependent sublytic injury in a model of membranous nephropathy. J Biol Chem (2010) 0.75
CYP2C19-mediated (S)-mephenytoin 4'-hydroxylation assayed by high-performance liquid chromatography with radiometric detection. Methods Mol Biol (2006) 0.75
Catalytic assays for human cytochrome P450: an introduction. Methods Mol Biol (2006) 0.75
High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation. Methods Mol Biol (2006) 0.75